Trends in biopharma innovation; report
Over the past 20 years, more than 700 New Active Substances (NASs) - new small and large molecular entities - have been successfully discovered, developed and authorized by regulatory bodies for use by patients.
More than 600 of those have been authorized by the US Food and Drug Administration for use in treating American patients. After a low point of just 19 NAS launches in 2008, the number steadily rose to 47 in 2015
A new QuintilesIMS Institute report Lifetime Trends in Biopharmaceutical Innovation: Recent Evidence and Implications, profiles NASs over the past 20 years - covering a molecule’s characteristics (including specialty, orphan, biologics and oncology segments) - as well as profiles of patent holders and companies that brought the medicines to market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze